Form 4 Tracker
Sara Bonstein

Chief Financial Officer; Director · 4 filings · Latest: Jun 11, 2026

INSMED Inc
Xilio Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
INSM
Sara BonsteinChief Financial OfficerJun 3, 2026
Sale
$102.272,404$245.9K69,082
INSM
Sara BonsteinJun 3, 2026
Proposed Sale
$102.272,404$245.9K
INSM
Sara BonsteinChief Financial OfficerMay 13, 2026
Sale
$116.188,272$961.0K71,486
INSM
Sara BonsteinMay 13, 2026
Proposed Sale
$116.188,272$961.0K
INSM
Sara BonsteinChief Financial OfficerFeb 3, 2026
Sale
$156.34748$116.9K79,758
INSM
Sara BonsteinFeb 3, 2026
Proposed Sale
$156.33748$116.9K
INSM
Sara BonsteinJan 8, 2026
Proposed Sale
$174.171,447$252.0K
INSM
Sara BonsteinJan 7, 2026
Proposed Sale
$175.171,678$293.9K
INSM
Sara BonsteinJan 6, 2026
Proposed Sale
$173.331,517$262.9K
INSM
Bonstein SaraJul 21, 2025
Proposed Sale
$102.6458,400$6.0M
INSM
Bonstein SaraJul 7, 2025
Proposed Sale
$95.8357,764$5.5M
INSM
Bonstein SaraJun 23, 2025
Proposed Sale
$101.7557,765$5.9M
INSM
Bonstein SaraJun 10, 2025
Proposed Sale
$89.0957,766$5.1M
INSM
Bonstein SaraJun 3, 2025
Proposed Sale
$71.501,579$112.9K
INSM
Bonstein SaraMay 14, 2025
Proposed Sale
$65.611,634$107.2K
INSM
Bonstein SaraMay 13, 2025
Proposed Sale
$67.818,870$601.5K
INSM
Bonstein SaraFeb 11, 2025
Proposed Sale
$80.0036,643$2.9M
INSM
Bonstein SaraFeb 6, 2025
Proposed Sale
$80.9029,000$2.3M
INSM
Bonstein SaraJan 10, 2025
Proposed Sale
$63.721,066$67.9K
INSM
Bonstein SaraJan 8, 2025
Proposed Sale
$66.041,464$96.7K

Page 1 of 2

Next →